Company Performance Metrics
Imviva Biotech is a clinical-stage biotechnology company that develops allogeneic CAR-T cell therapies for cancers and autoimmune diseases. The company engineers off-the-shelf CAR-T products designed to match the performance of autologous CAR-T while addressing manufacturing barriers, delays, and costs. Its work centers on the Imviva platform and
proprietary ANSWER technology, which combine gene editing and T-cell engineering to improve persistence, activity, and immune compatibility. Imviva’s pipeline includes investigational candidates such as CTD402 for T-cell acute lymphoblastic leukemia and CTA313 for systemic lupus erythematosus and lupus nephritis. Through clinical development, the company focuses on scalable cell-based medicines intended to expand access to CAR-T therapy.
